Heska Stock Forecast, Price & News

+6.51 (+2.56 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume180,094 shs
Average Volume70,889 shs
Market Capitalization$2.78 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HSKA News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

Heska logo

About Heska

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.03 out of 5 stars

Medical Sector

533rd out of 1,351 stocks

Diagnostic Substances Industry

5th out of 25 stocks

Analyst Opinion: 1.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Heska (NASDAQ:HSKA) Frequently Asked Questions

Is Heska a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Heska stock.
View analyst ratings for Heska
or view top-rated stocks.

What stocks does MarketBeat like better than Heska?

Wall Street analysts have given Heska a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Heska wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Heska's next earnings date?

Heska is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Heska

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) announced its quarterly earnings data on Tuesday, August, 3rd. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.13. The medical research company had revenue of $64.93 million for the quarter, compared to analysts' expectations of $56.82 million. Heska had a negative net margin of 0.59% and a positive trailing twelve-month return on equity of 1.42%. The company's revenue for the quarter was up 42.0% compared to the same quarter last year.
View Heska's earnings history

How has Heska's stock price been impacted by COVID-19 (Coronavirus)?

Heska's stock was trading at $81.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSKA shares have increased by 218.8% and is now trading at $260.86.
View which stocks have been most impacted by COVID-19

What guidance has Heska issued on next quarter's earnings?

Heska issued an update on its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $250 million-$260 million, compared to the consensus revenue estimate of $245.24 million.

What price target have analysts set for HSKA?

5 Wall Street analysts have issued 12-month target prices for Heska's shares. Their forecasts range from $195.00 to $310.00. On average, they anticipate Heska's share price to reach $263.00 in the next year. This suggests a possible upside of 0.8% from the stock's current price.
View analysts' price targets for Heska
or view top-rated stocks among Wall Street analysts.

Who are Heska's key executives?

Heska's management team includes the following people:
  • Kevin S. Wilson, President, Chief Executive Officer & Director
  • Nancy Wisnewski, Chief Operating Officer & Executive Vice President
  • Catherine I. Grassman, Chief Financial Officer & Executive Vice President
  • Glenn R. Frank, Vice President-Research & Development
  • Steven M. Eyl, Chief Commercial Officer & Executive VP

What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska CEO Kevin S. Wilson on Kevin S. Wilson has an approval rating of 57% among Heska's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Heska's key competitors?

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (16.58%), Vanguard Group Inc. (6.11%), State Street Corp (3.15%), Wells Fargo & Company MN (2.36%), Invesco Ltd. (2.27%) and Dimensional Fund Advisors LP (2.19%). Company insiders that own Heska stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends for Heska

Which major investors are selling Heska stock?

HSKA stock was sold by a variety of institutional investors in the last quarter, including abrdn plc, Millennium Management LLC, Renaissance Technologies LLC, Monarch Partners Asset Management LLC, Russell Investments Group Ltd., FMR LLC, JPMorgan Chase & Co., and Tudor Investment Corp Et Al. Company insiders that have sold Heska company stock in the last year include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski, and Sharon J Larson.
View insider buying and selling activity for Heska
or view top insider-selling stocks.

Which major investors are buying Heska stock?

HSKA stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Invesco Ltd., BlackRock Inc., Goldman Sachs Group Inc., State Street Corp, Axiom Investors LLC DE, Nuveen Asset Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Heska
or or view top insider-buying stocks.

How do I buy shares of Heska?

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $260.86.

How much money does Heska make?

Heska has a market capitalization of $2.78 billion and generates $197.32 million in revenue each year. The medical research company earns $-14,400,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How many employees does Heska have?

Heska employs 602 workers across the globe.

What is Heska's official website?

The official website for Heska is

Where are Heska's headquarters?

Heska is headquartered at 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at (970) 493-7272 or via email at [email protected]

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.